All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
⭐Multiple Myeloma Hub spotlight: Updated data from the phase II CARTITUDE-2 trial ⭐
At European Hematology Association Congress 2024, Wilfried Roeloffzen discussed results from Cohort D of the phase II CARTITUDE-2 trial (NCT04133636) investigating the safety and efficacy of cilta-cel in patients with clinically high-risk newly diagnosed multiple myeloma who achieved less than a complete response after stem cell transplantation as frontline therapy (N = 17). The primary endpoint of measurable residual disease negativity was achieved in 80% of patients. The overall response rate was 94.1%, 18-month duration of response rate was 93.3%, and 18-month progression-free survival and overall survival rates were 93.8% each, highlighting promising efficacy of cilta-cel with or without lenalidomide maintenance in these patients.